Elan and PPD, Inc. have entered into a global business collaboration in order to advance the development of Elan’s portfolio. The goal of the cooperation is to leverage both companies’ expertise in a flexible, integrated manner to facilitate Elan’s clinical programs globally.
PPD will serve as Elan’s primary service provider for all development functions and activities. Elan will retain ownership of its assets and will be responsible for all decisions regarding strategy and progression of candidates, as well as the overall portfolio. Elan will leverage PPD’s capabilities across project and data management, biostatistics, regulatory, clinical and medical monitoring, quality assurance, pharmacovigilance and other areas. The two companies will work together to build upon this initial relationship and explore opportunities to maximize respective competencies in order to advance Elan’s portfolio. Financial terms and timelines were not disclosed.
"Establishing this strategic collaboration with PPD will enable Elan to accelerate the progression of our science into the clinical development setting in a rapid and global fashion,” said Eliseo Salinas, chief medical officer, executive vice president and head of development for Elan. “The ability to fluidly access additional expertise and execution capability on a global scale will complement our internal talent and may enable us to move multiple programs forward in a parallel manner.”
David Grange, chief executive officer of PPD, added, “PPD and Elan have established an innovative relationship structure that enables Elan to continue to invest in and advance its world-leading work in biology and its broad application in neuroscience, while leveraging PPD’s expertise and execution capabilities across key program areas on a global scale. This relationship brings together the strongest resources of both companies, and we are pleased to have created this unique and strategic business arrangement with Elan.”
沪公网安备31010402003309号